Roche said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics ...

The the Swiss drugmaker will face off in the obesity area with leaders Novo Nordisk A/S and Indianapolis-based Eli Lilly and ...

Roche Holding AG has more than five medicines that it could combine with weight-loss drugs, Chief Executive Officer Thomas ...

Roche (RHHBY) reportedly sees three obesity/diabetes drug candidates acquired through its takeover of Carmot having the ...

The pharma company said it believes there’s plenty of room for multiple industry players in the obesity drug market.

The Temperature-Activated Generation of Signal (TAGS) technology was developed by Roche for its high-throughput PCR-based instruments.

Roche focuses on obesity drug development, fast-tracking its CT-388 candidate, and targeting $3.6 billion in annual sales.

Roche RHHBY announced an asset purchase agreement with clinical-stage biotechnology company Regor Therapeutics. Per the ...

Roche’s current pharmaceutical portfolio will deliver growth through at least 2027, the company said. Schinecker has already ...

Irishman congratulates Slovenian as first man in 37 years to win the World Championships, Giro d'Italia and Tour de France ...

Roche argued that its obesity medications would prove to have advantages over its rivals’ — and that the demand for weight ...

In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Hold rating on Roche Holding AG (RHHVF – Research ...